Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • Parag Parikh Large Cap NFO on Jan 19: Can smart execution beat expensive active funds? 
    • Can the SIP-3 Upgrade Spark a Rally?
    • Mutual Funds’ Assets Triple in 3 Years
    • Crypto Market Slide Hits ARK ETFs as Coinbase, Roblox Weigh on Returns
    • AI bonds could devour credit markets. Let stock investors take the risk.
    • 6 Top-Performing Large-Blend Funds | Morningstar
    • Active ETFs: 9 Charts on a Record Year
    • Lunate launches Boreas range of Thematic ETFs in Europe
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Funds»COSCIENS Biopharma – Conclusion d’un accord de résolution avec Goodwood, Goodwood Fund et Puccetti Funds Management
    Funds

    COSCIENS Biopharma – Conclusion d’un accord de résolution avec Goodwood, Goodwood Fund et Puccetti Funds Management

    May 30, 2025


    Logo COSCIENS Biopharma Inc.

    COSCIENS Biopharma Inc, anciennement Aeterna Zentaris Inc, est une société biopharmaceutique spécialisée dans le développement et la commercialisation d’un portefeuille diversifié de produits pharmaceutiques et diagnostiques, y compris ceux qui sont axés sur des domaines où les besoins médicaux ne sont pas satisfaits. Son produit principal, la macimoréline (Macrilen ; Ghryvelin), est un test oral indiqué pour le diagnostic de la déficience en hormone de croissance chez l’adulte (DHCA). La société est également engagée dans le développement d’actifs thérapeutiques et d’une technologie d’extraction propriétaire, qui est appliquée à la production d’ingrédients actifs à partir de ressources végétales renouvelables utilisées dans les produits cosméceutiques (c’est-à-dire le bêta-glucane d’avoine et les avenanthramides, que l’on trouve dans des marques de produits de soins de la peau comme Aveeno et Burt’s Bees) et qui sont en cours de développement en tant que nutraceutiques et/ou produits pharmaceutiques potentiels.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    6 Top-Performing Large-Blend Funds | Morningstar

    January 15, 2026

    Devang on fixed income: Two tactical opportunities in Gilt and Accrual funds

    January 14, 2026

    IntegraFin reports record funds after Budget volatility

    January 13, 2026
    Leave A Reply Cancel Reply

    Top Posts

    The Shifting Landscape of Art Investment and the Rise of Accessibility: The London Art Exchange

    September 11, 2023

    Charlie Cobham: The Art Broker Extraordinaire Maximizing Returns for High Net Worth Clients

    February 12, 2024

    Can the SIP-3 Upgrade Spark a Rally?

    January 15, 2026

    The Unyielding Resilience of the Art Market: A Historical and Contemporary Perspective

    November 19, 2023
    Don't Miss
    Mutual Funds

    Parag Parikh Large Cap NFO on Jan 19: Can smart execution beat expensive active funds? 

    January 15, 2026

    PPFAS Mutual Fund has announced the new fund offer (NFO) dates for the Parag Parikh…

    Can the SIP-3 Upgrade Spark a Rally?

    January 15, 2026

    Mutual Funds’ Assets Triple in 3 Years

    January 15, 2026

    Crypto Market Slide Hits ARK ETFs as Coinbase, Roblox Weigh on Returns

    January 15, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Financial adviser linked to Shield and First Guardian collapsed super funds is accused of hiding $14million Cayman Islands company from ASIC

    October 23, 2025

    Fox Is Making Some Weird Business Deals

    November 19, 2025

    Guinness-owner Diageo sells €1.9 billion in euro bonds

    August 29, 2024
    Our Picks

    Parag Parikh Large Cap NFO on Jan 19: Can smart execution beat expensive active funds? 

    January 15, 2026

    Can the SIP-3 Upgrade Spark a Rally?

    January 15, 2026

    Mutual Funds’ Assets Triple in 3 Years

    January 15, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    ₹10,000 monthly SIP in this mutual fund has grown to ₹1.52 crore in 22 years

    September 17, 2025
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.